Performance of Donor‐Derived Cell‐Free DNA in Surveillance and For‐Cause Biopsies in Pediatric Kidney Transplant Recipients
Pediatric Transplantation · 2025-12 · 29 (8)
DOI: 10.1111/petr.70215 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Transplantation, online erschienen am 30.10.2025. Verfasst von Stella Kilduff und 5 weiteren Autor:innen. Beteiligte Einrichtung: Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Kidney Transplantation, Graft Rejection, Cell-Free Nucleic Acids, Kidney. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Siragusa Transplantation Center at Ann & Robert H. Lurie Children's Hospital of Chicago.
Abstract (Originalsprache)
Background
Donor‐derived cell‐free DNA (dd‐cfDNA), a biomarker demonstrated to increase with allograft injury, has been considered a possible diagnostic tool for allograft rejection in place of the current gold standard which is invasive kidney biopsies. We tested whether dd‐cfDNA levels were predictive of rejection in our single‐center cohort of pediatric kidney transplant (KT) recipients.
Methods
All primary pediatric KT recipients that had a dd‐cfDNA level obtained within a month of any kidney biopsy, either surveillance or for‐cause were included. Descriptive analysis was performed stratified by rejection status. Univariate analysis was performed to assess the association between median dd‐cfDNA levels and rejection by each biopsy time point. dd‐cfDNA levels were then further stratified by rejection type (no rejection, T‐cell mediated, antibody mediated, or mixed). Diagnostic performance metrics of dd‐cfDNA for detecting rejection were evaluated.
Results
Forty pediatric KT recipients had 44 biopsies, 21 (48%) of which demonstrated rejection. Acute cellular, antibody‐mediated, and mixed rejection occurred in 12 (57%), 6 (29%), and 3 (14%) respectively. The median dd‐cfDNA level at the time of biopsy in those with and without rejection was 1.7 (95% CI: 0.2, 3.3) and 0.3 (95% CI: 0.2, 0.7), respectively ( p = 0.15). dd‐cfDNA levels prior to for‐cause biopsies were significantly higher in patients with rejection (0.3 vs. 2.7; p = 0.02). dd‐cfDNA levels at surveillance biopsies did not differ significantly by rejection status or type of rejection. dd‐cfDNA levels ≥ 1 diagnosed rejection with a sensitivity of 52% and specificity of 83%.
Conclusions
Elevated dd‐cfDNA levels were associated with rejection in for‐cause biopsies but not in surveillance biopsies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA.
- Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
ORCID-Profile: Stella Kilduff, Debora Matossian, Priya S Verghese
Förderung
- Siragusa Transplantation Center at Ann & Robert H. Lurie Children's Hospital of Chicago
Zitieren
APA
Kilduff, S., Fishbein, J., Becerril-Romero, C., Switalski, M., Matossian, D., & Verghese, P. S. (2025). Performance of Donor‐Derived Cell‐Free DNA in Surveillance and For‐Cause Biopsies in Pediatric Kidney Transplant Recipients. Pediatric Transplantation, 29(8). https://doi.org/10.1111/petr.70215
Vancouver
Kilduff S, Fishbein J, Becerril-Romero C, Switalski M, Matossian D, Verghese PS. Performance of Donor‐Derived Cell‐Free DNA in Surveillance and For‐Cause Biopsies in Pediatric Kidney Transplant Recipients. Pediatric Transplantation. 2025;29(8). doi:10.1111/petr.70215
BibTeX
@article{Kilduff2025,
author = {Kilduff, Stella and Fishbein, Joseph and Becerril-Romero, Carlos and Switalski, Matthew and Matossian, Debora and Verghese, Priya S},
title = {Performance of Donor‐Derived Cell‐Free DNA in Surveillance and For‐Cause Biopsies in Pediatric Kidney Transplant Recipients},
journal = {Pediatric Transplantation},
year = {2025},
volume = {29},
number = {8},
doi = {10.1111/petr.70215}
}
EUVIMED